NCT05169567
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with symptomatic or untreated central nervous system metastasis; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05169567